Related Experiment Video
Updated: Aug 8, 2026

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
Published on: May 27, 2021
[Quo vadetis coxibs?]
1Klinika za reumatologiju, fizikalnu medicinu i i rehabilitaciju Klinicka bolnica Sestre milosrdnice, Zagreb. simeon.grazio@zg.t-com.hr
Abstract:
After the withdrawall of rofecoxib from worldwide market, there is ongoing debate whether gastrointestinal safety of COX-2 inhibition compared to non-selective NSAID-s may come at the cost of increased cardiovascular events. In this paper the relevant data regarding mechanisms, effects and side effects of selected COX-2 inhibitors are presented. Possible class effect is disscused and proposed alternative therapies.
Related Concept Videos
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Antihypertensive Drugs: Vasodilators
Drugs for Treatment of Ulcerative Colitis in IBD
Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...